The principal objective of this pilot study is to determine whether the progression of
chronic antibody-mediated rejection (ABMR) could be minimized by the post-transplant
administration of high dose of Intravenous Immunoglobulins (IVIg).
We test the hypothesis that repetitive IVIg administration reduces or stabilize the
progressive loss of transplant function and the evolution to chronic ABMR in stable kidney
transplant patients with HLA-DSA developed post-transplantion (de novo HLA-DSA) and
concomitant humoral graft injury.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Association ASLUMARE CSL Behring
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin